NYSE:EOG
NYSE:EOGOil and Gas

A Look At EOG Resources (EOG) Valuation After Recent Share Price Rebound

Framing EOG Resources after recent performance EOG Resources (EOG) has drawn fresh attention after a recent rebound, with the stock up 2.5% over the past day and 8% over the past week. This movement invites a closer look at its fundamentals. See our latest analysis for EOG Resources. While the recent 7 day share price return of 7.99% and 1 month share price return of 4.54% suggest short term momentum is building, the 1 year total shareholder return of 16.41% decline and 3 year total...
NasdaqGS:EZPW
NasdaqGS:EZPWConsumer Finance

A Look At EZCORP (EZPW) Valuation After Earnings Beat And Rating Shift

Why EZCORP’s latest earnings and rating shift matter for investors EZCORP (EZPW) recently reported quarterly earnings that exceeded analyst expectations, coinciding with a move from a “strong-buy” to “buy” rating at one research outlet while other brokerages kept positive views in place. This combination of strong results and a modest rating change gives you a fresh data point to consider when assessing how the pawn-focused lender’s current share price compares with its recent performance and...
NasdaqGS:ALMS
NasdaqGS:ALMSPharmaceuticals

Alumis (ALMS) Is Up 35.8% After Psoriasis Data And $300M Raise Has The Bull Case Changed?

Earlier in January 2026, Alumis Inc. reported positive topline Phase 3 ONWARD1 and ONWARD2 results for its oral TYK2 inhibitor envudeucitinib in moderate-to-severe plaque psoriasis and subsequently completed a US$300.05 million follow-on common stock offering at US$17.00 per share. A key angle for investors is how envudeucitinib’s differentiated clinical profile and “pipeline-in-a-pill” potential, including possible applications in systemic lupus erythematosus, could influence Alumis’s...
NasdaqGS:CAI
NasdaqGS:CAIBiotechs

Could Caris Life Sciences (CAI)–Everlywell Cancer Test Tie-Up Redefine Its Precision Medicine Positioning?

In early January 2026, Caris Life Sciences announced a partnership with digital health company Everlywell to launch Caris Detect, a multi-cancer early detection blood test that applies whole genome sequencing and AI to identify molecular signals of cancer in the bloodstream, with commercialization planned through Everlywell’s platform in the first half of 2026. This collaboration highlights how advanced genomic screening and consumer-focused digital health distribution could broaden access...
NYSE:RHI
NYSE:RHIProfessional Services

Is Leadership Recognition and Stabilizing Demand Quietly Reframing the Investment Case for Robert Half (RHI)?

Recently, two senior Robert Half executives, Paul F. Gentzkow and George Denlinger, were named to Staffing Industry Analysts’ 2026 North America Staffing 100 list, recognizing their long-term leadership in talent and consulting services. This industry recognition, alongside commentary about resilient consulting operations and easing macroeconomic pressures, highlights how management strength may support Robert Half’s positioning in a gradually improving staffing landscape. We’ll now examine...
NYSE:ARE
NYSE:AREHealth Care REITs

A Look At Alexandria Real Estate Equities (ARE) Valuation After Lawsuits And Impairment-Linked Earnings Shock

Alexandria Real Estate Equities (ARE) is back in focus after investors filed multiple securities class action lawsuits related to its Long Island City property, following weaker than expected 2025 results and a large impairment charge. See our latest analysis for Alexandria Real Estate Equities. The latest legal actions and impairment news come after a volatile stretch where the share price return has recently improved, with a 30 day share price return of 18.41% and year to date share price...
NYSE:ASAN
NYSE:ASANSoftware

Is Asana (ASAN) Now An Opportunity After Extended Share Price Weakness

If you are wondering whether Asana's current share price reflects its true worth, you are not alone. This article focuses squarely on what the numbers say about value. At a last close of US$11.42, the stock has seen a 15.7% decline over the past week, a 19.2% decline over the past month, an 11.9% decline year to date, and a 41.9% decline over the past year, with a 71.1% decline over five years and an 18.7% decline over three years. Recent attention on Asana has centered on how its work...
NasdaqGS:VIAV
NasdaqGS:VIAVCommunications

Is It Too Late To Consider Viavi Solutions (VIAV) After Its 75% One Year Surge?

If you are wondering whether Viavi Solutions at around US$17.80 is still good value after a strong run, you are not alone. The stock has pulled back 4.0% over the last week and is slightly lower over the past month and year to date, yet it is still up 75.5% over 1 year and 59.8% over 3 years, with a 5 year return of 9.7%. Recently, news flow around Viavi Solutions has focused on its role as a provider of network testing and monitoring equipment, particularly for telecoms and data center...
NYSE:IMAX
NYSE:IMAXEntertainment

Is IMAX (IMAX) Still Attractive After 54% 1-Year Surge And DCF Upside?

If you are wondering whether IMAX at around US$35.07 is still good value after its run, this article will walk through what the current share price might be implying. The stock has had a mixed run recently, with a 2.8% gain over the last week, a 10.2% decline over the last month, and returns of 54.0% over 1 year, 120.6% over 3 years, and 88.3% over 5 years. Recent attention on IMAX has centered on box office trends and its position in premium large format cinema, as investors assess how...
NYSE:NOW
NYSE:NOWSoftware

A Look At ServiceNow (NOW) Valuation After Recent Share Price Weakness

Context for ServiceNow’s recent share performance ServiceNow (NOW) has been under pressure recently, with the stock showing a 2.6% decline over the past day, a 10.8% drop over the past week, and deeper losses over the past month and past 3 months. See our latest analysis for ServiceNow. Zooming out, ServiceNow’s recent share price weakness, including the 1 year total shareholder return of 36.15% in the red and the year to date share price return of 8.71% in the red, points to fading momentum...
NYSE:AES
NYSE:AESRenewable Energy

Assessing AES (NYSE:AES) Valuation After Panama LNG Lawsuit Draws Investor Attention

Why a Panama LNG lawsuit has put AES (AES) under the spotlight A new civil lawsuit in Virginia, accusing AES (AES) of working with partners to exclude Sinolam from Panama’s LNG to power market and seeking over US$4b in damages, has sharply focused investor attention. See our latest analysis for AES. At a share price of US$14.00, AES has a year to date share price return of a 5.53% decline, while the 1 year total shareholder return of 26.25% contrasts with a 3 year total shareholder return of...
NasdaqGS:LAMR
NasdaqGS:LAMRSpecialized REITs

Is Lamar Advertising (LAMR) Pricing Reflect Its DCF Upside And Billboard Growth Story

If you are wondering whether Lamar Advertising at around US$130.78 is offering fair value today, you are not alone. This article will walk through what that price really buys you as an investor. The stock has recently posted returns of 2.8% over 7 days, 3.0% over 30 days, 5.4% year to date, 15.5% over 1 year, 50.2% over 3 years and 97.4% over 5 years, so recent performance is front of mind for many holders. Recent headlines around Lamar Advertising have mainly focused on its position in the...
NYSE:WSO
NYSE:WSOTrade Distributors

A Look At Watsco (WSO) Valuation After Recent Mixed Share Price Performance

What recent performance says about Watsco (WSO) Without a specific news headline driving attention today, Watsco (WSO) is drawing interest after a mixed run for shareholders, with a 1 day decline, solid recent gains, and a weaker past year overall. See our latest analysis for Watsco. At a share price of $372.51, Watsco has paired a 7 day share price return of 6.6% and a 1 month share price return of 8.1% with a weaker 1 year total shareholder return of 20.2% and stronger multi year gains...
NasdaqGS:QCOM
NasdaqGS:QCOMSemiconductor

Assessing Qualcomm (QCOM) After Recent Share Price Pullback In Chip Sector Repricing

If you are wondering whether QUALCOMM is priced fairly or if the recent pullback has created an opportunity, this article walks through the key numbers so you can judge the current price for yourself. After a 7 day return of an 8.7% decline and a 30 day return of an 8.2% decline, QUALCOMM now sits at a last close of US$164.54, with returns of a 4.9% decline year to date, 2.3% over 1 year, 44.3% over 3 years, and 11.3% over 5 years. Recent headlines around QUALCOMM have focused on its role in...
NasdaqGS:HOLX
NasdaqGS:HOLXMedical Equipment

Is It Time To Reconsider Hologic (HOLX) After Mixed Returns And DCF Upside?

If you are wondering whether Hologic’s current share price reflects its underlying worth, this article will walk through what the numbers are actually saying about value. The stock last closed at US$75.16, with returns of 0.3% over the past week, around 0.0% over the last month, 0.8% year to date, 9.3% over 1 year, a 4.8% decline over 3 years, and a 2.7% decline over 5 years, which gives you a mixed picture of recent and longer term performance. Recent coverage around Hologic has focused on...
NYSEAM:KULR
NYSEAM:KULRElectrical

A Look At KULR Technology Group (KULR) Valuation After New Five Year Caban Energy Supply Agreement

KULR Technology Group (KULR) drew investor attention after securing a five year preferred battery supply agreement with Caban Energy, a deal projected to generate about US$30 million in revenue starting in 2026. See our latest analysis for KULR Technology Group. The Caban agreement lands as momentum in KULR Technology Group's shares has picked up recently, with a 1 month share price return of 21.26% and a year to date share price return of 26.56%. However, the 1 year total shareholder return...
NYSE:BFLY
NYSE:BFLYMedical Equipment

Is Butterfly Network (BFLY) Turning Its Ultrasound Platform Into a Stickier AI Ecosystem Advantage?

Earlier this month, Butterfly Network, Inc. announced plans to release its Beam Steering API in the first half of 2026, opening previously internal capabilities like iQ Slice™ and iQ Fan™ to external developers within its Butterfly Garden™ and Ultrasound-on-Chip™ programs. This move could broaden third-party AI innovation around Butterfly’s platform and make high-quality portable ultrasound imaging more accessible to clinicians with varying experience levels across multiple care...
NasdaqGM:ATRC
NasdaqGM:ATRCMedical Equipment

Does AtriCure’s (ATRC) Push Toward Positive EBITDA Recast Its Long‑Term Investment Narrative?

In January 2026, AtriCure reported preliminary 2025 results and issued 2026 guidance, projecting approximately US$600 million to US$610 million in revenue and expecting positive adjusted EBITDA, net income, and cash flow, while also highlighting new product launches and completion of enrollment in a key clinical trial. The company simultaneously extended its asset-based revolving credit facility by three years on improved terms, lowering interest costs and adding flexibility that could...
NYSE:LEVI
NYSE:LEVILuxury

Is Levi Strauss (LEVI) Still Attractively Priced After Its Recent Share Price Run?

If you are wondering whether Levi Strauss is still reasonably priced after its recent run, you are not alone. This article focuses squarely on what you might be paying for each dollar of the business. The share price recently closed at US$21.46, with returns of 0.8% over the last week, a 2.2% decline over the last month, and gains of 3.1% year to date, 24.7% over 1 year, 44.5% over 3 years and 14.8% over 5 years. Recent headlines around Levi Strauss have centered on brand strength, product...
NasdaqGS:ONC
NasdaqGS:ONCBiotechs

HERIZON-GEA-01 Phase 3 Zanidatamab Combo Data Might Change The Case For Investing In BeOne Medicines (ONC)

BeOne Medicines recently presented full Phase 3 HERIZON-GEA-01 results for ZIIHERA (zanidatamab) plus TEVIMBRA (tislelizumab) and chemotherapy in first‑line HER2-positive gastroesophageal adenocarcinoma at the 2026 ASCO GI Cancers Symposium in San Francisco, including an interim overall survival analysis. The regimen’s high overall response rate and prolonged median duration of response, combined with BeOne’s commercial rights to ZIIHERA across much of Asia Pacific, elevate the potential...
NasdaqGS:ATRO
NasdaqGS:ATROAerospace & Defense

Assessing Astronics (ATRO) Valuation After Strong Preliminary 2025 Results And 2026 Revenue Outlook

Astronics (ATRO) recently prompted renewed attention after releasing preliminary unaudited revenue figures for Q4 and full year 2025 that came in above its prior guidance, along with early revenue expectations for 2026. See our latest analysis for Astronics. The upbeat revenue update appears to have fed directly into sentiment, with Astronics’ 1-day share price return of 6.28% and 30-day share price return of 36.84% sitting alongside a very large 1-year total shareholder return and a multi...
NasdaqCM:DUOT
NasdaqCM:DUOTSoftware

Will Duos’ Rural Edge Data Center Push in Texas Reshape Duos Technologies Group's (DUOT) Narrative

Duos Technologies Group, through its Duos Edge AI subsidiary, recently deployed a patented modular Edge Data Center in Hereford, Texas, in partnership with the Hereford Independent School District to bolster low-latency computing for education and local users. This initiative highlights Duos’ push into rural and underserved markets, using repeatable, capital-efficient edge infrastructure that targets recurring revenue and broader digital access. We’ll now examine how this rural edge data...
NYSE:HCC
NYSE:HCCMetals and Mining

Is Warrior Met Coal (HCC) Pricing Reflect Its Strong 1-Year Rally And DCF Outlook

If you are wondering whether Warrior Met Coal's current price reflects its true worth, you are not alone. The stock invites a closer look at what you are actually paying for the underlying business. At a recent close of US$102.08, the share price sits alongside returns of 11.2% over 7 days, 22.2% over 30 days, 14.0% year to date and 90.5% over 1 year, with a very large gain over 5 years. These price moves sit against ongoing interest in coal producers and how investors are weighing long term...
NasdaqGM:PSNY
NasdaqGM:PSNYAuto

Polestar (PSNY) Valuation Check After Strong Retail Sales Growth And Recent Share Price Rebound

Polestar’s latest sales update Polestar Automotive Holding UK (PSNY) reported retail sales of 15,608 cars in the fourth quarter of 2025, compared with 12,256 a year earlier, and 60,119 cars for the full year versus 44,851 previously. See our latest analysis for Polestar Automotive Holding UK. The strong retail sales update comes after a sharp 61.61% 1 month share price return. However, the 1 year total shareholder return is still a 40.66% loss and the 3 year total shareholder return is an...